Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Endocrine Pathology
Published in: Endocrine Pathology 4/2012

01-12-2012

Adequacy of Pathology Reports of Specimens from Patients with Differentiated Thyroid Cancer

Authors: Ma Luisa Isidro, Gloria Lugo, Olga Fidalgo, Sara García-Arias

Published in: Endocrine Pathology | Issue 4/2012

Login to get access

Abstract

This study aims to investigate the adequacy of pathology reports of specimens from patients with differentiated thyroid cancer (DTC) operated in our institution. Retrospective analysis of the pathology reports of all patients diagnosed with DTC in our area, from 1 January 2006 through 30 June 2011, was done. Sixty-eight patients were diagnosed with DTC. All reports were descriptive. In all the reports, but one, one or more core data items (according to the Royal College of Pathologists) were missing. Information about 1 and 2 items was lacking in 7.4 and 42.6 % of the reports, respectively. The rest were missing three or more data. Lymphovascular invasion, histology subtype, and completeness of excision were, in this order, the three most frequently omitted data. Sometimes, the information in question was not explicitly expressed but could be extrapolated from the data available. The pathology reports of DTC specimens frequently miss some of the information considered necessary to provide a comprehensive patient care.
Literature
1.
Vaisman F, Momesso D, Bulzico D, Pessoa C, Dias F, Corbo R, et al. (2012) Spontaneous remission in thyroid cancer patients after biochemical incomplete response to initial therapy. Clin Endocrinol 77:132–138CrossRef
2.
Loh KC, Greenspan FS, Gee L, Miller TR, Yeo PP (1997) Pathological tumor-node-metastasis (pTNM) staging for papillary and follicular thyroid carcinomas: a retrospective analysis of 700 patients. J Clin Endocrinol Metab 82:3553–3562.PubMedCrossRef
3.
Cooper DS, Doherty GM, Haugen BR, Hauger BR, Kloos RT, Lee SL, et al. (2009) Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 19:1167–1214.PubMedCrossRef
4.
Bilimoria KY, Bentrem DJ, Ko CY, Stewart AK, Winchester DP, Talamonti MS, et al. (2007) Extent of surgery affects survival for papillary thyroid cancer. Ann Surg 246:375–381.PubMedCrossRef
5.
Hay ID, Bergstralh EJ, Goellner JR, Ebersold JR, Grant CS (1993) Predicting outcome in papillary thyroid carcinoma: development of a reliable prognostic scoring system in a cohort of 1779 patients surgically treated at one institution during 1940 through 1989. Surgery 114:1050–1057.PubMed
6.
Hay ID, Thompson GB, Grant CS, Bergstralh EJ, Dvorak CE, Gorman CA, et al. (2002) Papillary thyroid carcinoma managed at the Mayo Clinic during six decades (1940–1999): temporal trends in initial therapy and long-term outcome in 2444 consecutively treated patients. World J Surg 26:879–885.PubMedCrossRef
7.
Sanders LE, Cady B (1998) Differentiated thyroid cancer: reexamination of risk groups and outcome of treatment. Arch Surg 133:419–425.PubMedCrossRef
8.
Ito Y, Kudo T, Kobayashi K, Miya A, Ichihara K, Miyauchi A (2012) Prognostic Factors for Recurrence of Papillary Thyroid Carcinoma in the Lymph Nodes, Lung, and Bone: Analysis of 5,768 Patients with Average 10-year Follow-up. World J Surg 36:1274–1278.PubMedCrossRef
9.
Jung TS, Kim TY, Kim KW, Oh YL, Park dJ, Cho BY, et al. (2007) Clinical features and prognostic factors for survival in patients with poorly differentiated thyroid carcinoma and comparison to the patients with the aggressive variants of papillary thyroid carcinoma. Endocr J 54:265–274.
10.
Kazaure HS, Roman SA, Sosa JA (2011) Aggressive Variants of Papillary Thyroid Cancer: Incidence, Characteristics and Predictors of Survival among 43,738 Patients. Ann Surg Oncol 19:1874–1880.PubMedCrossRef
11.
Morris LG, Shaha AR, Tuttle RM, Sikora AG, Ganly I (2010) Tall-cell variant of papillary thyroid carcinoma: a matched-pair analysis of survival. Thyroid 20:153–158.PubMedCrossRef
12.
Kushchayeva Y, Duh QY, Kebebew E, D’Avanzo A, Clark OH (2008) Comparison of clinical characteristics at diagnosis and during follow-up in 118 patients with Hurthle cell or follicular thyroid cancer. Am J Surg 195:457–462.PubMedCrossRef
13.
Gulcelik MA, Gulcelik NE, Kuru B, Camlibel M, Alagol H (2007) Prognostic factors determining survival in differentiated thyroid cancer. J Surg Oncol 96:598–604.PubMedCrossRef
14.
D’Avanzo A, Ituarte P, Treseler P, Kebebew E, Wu J, Wong M, et al. (2004) Prognostic scoring systems in patients with follicular thyroid cancer: a comparison of different staging systems in predicting the patient outcome. Thyroid 14:453–458.PubMedCrossRef
15.
Rouxel A, Hejblum G, Bernier MO, Boëlle PY, Ménégaux F, Mansour G, et al. (2004) Prognostic factors associated with the survival of patients developing loco-regional recurrences of differentiated thyroid carcinomas. J Clin Endocrinol Metab 89:5362–5368.PubMedCrossRef
16.
Podnos YD, Smith D, Wagman LD, Ellenhorn JD (2005) The implication of lymph node metastasis on survival in patients with well-differentiated thyroid cancer. Am Surg 71:731–734.PubMed
17.
Silver CE, Owen RP, Rodrigo JP, Rinaldo A, Devaney KO, Ferlito A (2011) Aggressive variants of papillary thyroid carcinoma. Head Neck 33:1052–1059.PubMedCrossRef
18.
Sugino K, Kameyama K, Ito K, Nagahama M, Kitagawa W, Shibuya H, et al. (2012) Outcomes and prognostic factors of 251 patients with minimally invasive follicular thyroid carcinoma. Thyroid 22:798–804.PubMedCrossRef
19.
Ito Y, Kudo T, Kihara M, Takamura Y, Kobayashi K, Miya A, et al. (2012) Prognosis of low-risk papillary thyroid carcinoma patients: its relationship with the size of primary tumors. Endocr J 59:119–125.PubMedCrossRef
20.
Pacini F, Schlumberger M, Dralle H, Elisei R, Smit JW, Wiersinga W, et al. (2006) European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium. Eur J Endocrinol 154:787–803.PubMedCrossRef
21.
22.
23.
24.
Rosai J, Carcangiu ML, DeLellis RA, Simoes MS (2000) Recommendations for the reporting of thyroid carcinomas. Association of Directors of Anatomic and Surgical Pathology. Hum Pathol 31:1199–1201.PubMedCrossRef
25.
Kahn C, Simonella L, Sywak M, Boyages S, Ung O, O’Connell D (2012) Postsurgical Pathology Reporting of Thyroid Cancer in New South Wales, Australia. Thyroid 22:604–810.PubMedCrossRef
26.
Persing S, James TA, Mace J, Goodwin A, Geller B (2011) Variability in the quality of pathology reporting of margin status following breast cancer surgery. Ann Surg Oncol 2011 18:3061–3065.PubMedCrossRef
27.
Shuch B, Pantuck AJ, Pouliot F, Finley DS, Said JW, Belldegrun AS, et al. (2011) Quality of pathological reporting for renal cell cancer: implications for systemic therapy, prognostication and surveillance. BJU Int 108:343–348.PubMedCrossRef
28.
Verleye L, Ottevanger PB, Kristensen GB, Ehlen T, Johnson N, van der Burg ME, et al. (2011) Quality of pathology reports for advanced ovarian cancer: are we missing essential information? An audit of 479 pathology reports from the EORTC-GCG 55971/NCIC-CTG OV13 neoadjuvant trial. Eur J Cancer 47:57–64.PubMedCrossRef
29.
Katz MH, Merchant NB, Brower S, Branda M, Posner MC, William Traverso L, et al. (2011) Standardization of surgical and pathologic variables is needed in multicenter trials of adjuvant therapy for pancreatic cancer: results from the ACOSOG Z5031 trial. Ann Surg Oncol 18:337–344.PubMedCrossRef
30.
Idowu MO, Bekeris LG, Raab S, Ruby SG, Nakhleh RE (2010) Adequacy of surgical pathology reporting of cancer: a College of American Pathologists Q-Probes study of 86 institutions. Arch Pathol Lab Med 134:969–974.PubMed
31.
Haydu LE, Holt PE, Karim RZ, Madronio CM, Thompson JF, Armstrong BK, et al. (2010) Quality of histopathological reporting on melanoma and influence of use of a synoptic template. Histopathology 56:768–774.PubMedCrossRef
32.
Jansen-Landheer ML, Krijnen P, Oostindiër MJ, Kloosterman-Boele WM, Noordijk EM, Nooij MA, et al. (2009) Improved diagnosis and treatment of soft tissue sarcoma patients after implementation of national guidelines: a population-based study. Eur J Surg Oncol 35:1326–1332.PubMedCrossRef
33.
Srigley JR, McGowan T, Maclean A, Raby M, Ross J, Kramer S, et al. (2009) Standardized synoptic cancer pathology reporting: a population-based approach. J Surg Oncol 99:517–524.PubMedCrossRef
34.
Yunker WK, Matthews TW, Dort JC. Making the most of your pathology: standardized histopathology reporting in head and neck cancer (2008) J Otolaryngol Head Neck Surg 37:48–55.PubMed
35.
Cady B, Rossi R (1988) An expanded view of risk-group definition in differentiated thyroid carcinoma. Surgery 104:947–953.PubMed
36.
Hay ID, Grant CS, Taylor WF, McConahey WM (1987) Ipsilateral lobectomy versus bilateral lobar resection in papillary thyroid carcinoma: a retrospective analysis of surgical outcome using a novel prognostic scoring system. Surgery 102:1088–1095.PubMed
37.
Lin HW, Bhattacharyya N (2010) Clinical behavior of follicular variant of papillary thyroid carcinoma: presentation and survival. Laryngoscope 120 Suppl 4:S163.
38.
Lang BH, Lo CY, Chan WF, Lam AK, Wan KY (2006) Classical and follicular variant of papillary thyroid carcinoma: a comparative study on clinicopathologic features and long-term outcome. World J Surg 30:752–758.PubMedCrossRef
39.
Lam AK, Lo CY, Lam KS (2005) Papillary carcinoma of thyroid: A 30-yr clinicopathological review of the histological variants. Endocr Pathol 16:323–330.PubMedCrossRef
40.
Zhang L, Wei WJ, Ji QH, Zhu YX, Wang ZY, Wang Y, et al. (2012) Risk factors for neck nodal metastasis in papillary thyroid microcarcinoma: a study of 1066 patients. J Clin Endocrinol Metab 97:1250–1257.PubMedCrossRef
41.
Ross DS, Litofsky D, Ain KB, Bigos T, Brierley JD, Cooper DS, et al. (2009) Recurrence after treatment of micropapillary thyroid cancer. Thyroid 19:1043–1048.PubMedCrossRef
42.
Livolsi VA, Baloch ZW (2012) On pathology reports of thyroid cancer specimens: what should the clinician expect? Thyroid 22:563–565.PubMedCrossRef
43.
Mete O, Rotstein L, Asa SL. Controversies in thyroid pathology: thyroid capsule invasion and extrathyroidal extension (2010) Ann Surg Oncol 17:386–391.PubMedCrossRef
44.
Sherman SI, Brierley JD, Sperling M, Ain KB, Bigos ST, Cooper DS, et al. (1998) Prospective multicenter study of thyroiscarcinoma treatment: initial analysis of staging and outcome. National Thyroid Cancer Treatment Cooperative Study Registry Group. Cancer 83:1012–1021.PubMedCrossRef
45.
Ito Y, Tomoda C, Uruno T, Takamura Y, Miya A, Kobayashi K, et al. (2006) Prognostic significance of extrathyroid extension of papillary thyroid carcinoma: massive but not minimal extension affects the relapse-free survival. World J Surg 30:780–786.PubMedCrossRef
46.
Ito Y, Tomoda C, Uruno T, Takamura Y, Miya A, Kobayashi K, et al. (2006) Minimal extrathyroid extension does not affect the relapse-free survival of patients with papillary thyroid carcinoma measuring 4 cm or less over the age of 45 years. Surg Today 36:12–18.PubMedCrossRef
47.
Nixon IJ, Ganly I, Patel S, Palmer FL, Whitcher MM, Tuttle RM, et al. (2011) The impact of microscopic extrathyroid extension on outcome in patients with clinical T1 and T2 well-differentiated thyroid cancer. Surgery 150:1242–1249.PubMedCrossRef
48.
Chung YS, Kim JY, Bae JS, Song BJ, Kim JS, Jeon HM, et al. (2009) Lateral lymph node metastasis in papillary thyroid carcinoma: results of therapeutic lymph node dissection. Thyroid 19:241–246.PubMedCrossRef
49.
Roh JL, Kim JM, Park CI (2008) Central cervical nodal metastasis from papillary thyroid microcarcinoma: pattern and factors predictive of nodal metastasis. Ann Surg Oncol 15:2482–2486.PubMedCrossRef
50.
Fridman MV, Savva NN, Krasko OV, Zborovskaya AA, Mankovskaya SV, Schmid KW, et al. (2012) Clinical and pathologic features of ‘sporadic’ papillary thyroid carcinoma registered in 2005–2008 years in children and adolescents of Belarus. Thyroid. doi:10.​1089/​thy.​2011-0005.
51.
Reddy RM, Grigsby PW, Moley JF, Hall BL (2006) Lymph node metastases in differentiated thyroid cancer under 2 cm. Surgery 140:1050–1054.PubMedCrossRef
52.
Decaussin M, Bernard MH, Adeleine P, Treilleux I, Peix JL, Pugeat M, et al. (2002) Thyroid carcinomas with distant metastases: a review of 111 cases with emphasis on the prognostic significance of an insular component. Am J Surg Pathol 26:1007–1015.PubMedCrossRef
53.
Gardner RE, Tuttle RM, Burman KD, Haddady S, Truman C, Sparling YH, et al. (2000) Prognostic importance of vascular invasion in papillary thyroid carcinoma. Arch Otolaryngol Head Neck Surg 126:309–312.PubMed
54.
Stack BC, Ferris RL, Goldenberg D, Haymart M, Shaha A, Sheth S, et al. (2012) American Thyroid Association Consensus Review and Statement Regarding the Anatomy, Terminology, and Rationale for Lateral Neck Dissection in Differentiated Thyroid Cancer. Thyroid 22:501–508.PubMedCrossRef
55.
Mete O, Asa SL (2011) Pathological definition and clinical significance of vascular invasion in thyroid carcinomas of follicular epithelial derivation. Mod Pathol 24:1545–1552.PubMedCrossRef
56.
Ito Y, Miyauchi A. Lateral lymph node dissection guided by preoperative and intraoperative findings in differentiated thyroid carcinoma (2008) World J Surg 32:729–739.PubMedCrossRef
57.
Mulla M, Schulte KM (2012) Central cervical lymph node metastases in papillary thyroid cancer: a systematic review of imaging-guided and prophylactic removal of the central compartment. Clin Endocrinol (Oxf) 76:131–136.CrossRef
58.
Moreno MA, Edeiken-Monroe BS, Siegel ER, Sherman SI, Clayman GL (2012) In papillary thyroid cancer, preoperative central neck ultrasound detects only macroscopic surgical disease, but negative findings predict excellent long-term regional control and survival. Thyroid 22:347–355.PubMedCrossRef
59.
Baek SK, Jung KY, Kang SM, Kwon SY, Woo JS, Cho SH, et al. (2010) Clinical risk factors associated with cervical lymph node recurrence in papillary thyroid carcinoma. Thyroid 20:147–152.PubMedCrossRef
60.
Carling T, Carty SE, Ciarleglio MM, Cooper DS, Doherty GM, Kim LT, et al. (2012) American thyroid association design and feasibility of a prospective randomized controlled trial of prophylactic central lymph node dissection for papillary thyroid carcinoma. Thyroid 22:237–244.PubMedCrossRef
61.
de Meer SG, Dauwan M, de Keizer B, Valk GD, Borel Rinkes IH, Vriens MR (2012) Not the number but the location of lymph nodes matters for recurrence rate and disease-free survival in patients with differentiated thyroid cancer. World J Surg 36:1262–1267.PubMedCrossRef
62.
Ito Y, Tomoda C, Uruno T, Takamura Y, Miya A, Kobayashi K, et al. (2005) Ultrasonographically and anatomopathologically detectable node metastases in the lateral compartment as indicators of worse relapse-free survival in patients with papillary thyroid carcinoma. World J Surg 29:917–920.PubMedCrossRef
63.
Smith VA, Sessions RB, Lentsch EJ (2012) Cervical lymph node metastasis and papillary thyroid carcinoma: Does the compartment involved affect survival? Experience from the SEER database. J Surg Oncol 106:357–362.PubMedCrossRef
64.
Lee YS, Lim YS, Lee JC, Wang SG, Kim IJ, Lee BJ (2010) Clinical implication of the number of central lymph node metastasis in papillary thyroid carcinoma: preliminary report. World J Surg 34:2558–2563.PubMedCrossRef
65.
Sugitani I, Kasai N, Fujimoto Y, Yanagisawa A (2004) A novel classification system for patients with PTC: addition of the new variables of large (3 cm or greater) nodal metastases and reclassification during the follow-up period. Surgery 135:139–148.PubMedCrossRef
66.
Aumann K, Amann D, Gumpp V, Hauschke D, Kayser G, May AM, et al. (2012) Template-based synoptic reports improve the quality of pathology reports of prostatectomy specimens. Histopathology 60:634–644.PubMedCrossRef
67.
Mohanty SK, Piccoli AL, Devine LJ, Patel AA, William GC, Winters SB, et al. (2007) Synoptic tool for reporting of hematological and lymphoid neoplasms based on World Health Organization classification and College of American Pathologists checklist. BMC Cancer 7:144–153.PubMedCrossRef
Metadata
Title
Adequacy of Pathology Reports of Specimens from Patients with Differentiated Thyroid Cancer
Authors
Ma Luisa Isidro
Gloria Lugo
Olga Fidalgo
Sara García-Arias
Publication date
01-12-2012
Publisher
Springer US
Published in
Endocrine Pathology / Issue 4/2012
Print ISSN: 1046-3976
Electronic ISSN: 1559-0097
DOI
https://doi.org/10.1007/s12022-012-9226-7

Other articles of this Issue 4/2012

Endocrine Pathology 4/2012 Go to the issue

OriginalPaper

Giant Amyloid Goiter in Crohn’s Disease

OriginalPaper

Pituitary Metastasis Presenting as Ischemic Pituitary Apoplexy Following Heparin-induced Thrombocytopenia

OriginalPaper

Lipid-Rich (“Clear Cell”) Neuroendocrine Tumors of the Pancreas in MEN I Patients

OriginalPaper

Biomarkers of Parathyroid Carcinoma

OriginalPaper

Prognostic and Predictive Markers in Medullary Thyroid Carcinoma

Report

Villous Papillary Thyroid Carcinoma: a Variant Associated with Marfan Syndrome
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits